Andere Sprachen Femasys Inc.

Aktien

A3CYX9

US31447E1055

FEMY

Markt geschlossen - Nasdaq Andere Börsenplätze 22:30:00 03.05.2024			% 5 Tage	% 1. Jan.
1,29 ^USD	+4,45 %		+1,57 %	+32,31 %

01.04.	FEMASYS INC. : Bewertung von HC Wainwright kaufen	ZM
28.03.	Femasys Inc. meldet Ergebnis für das am 31. Dezember 2023 endende Geschäftsjahr	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Femasys CEO and Founder Kathy Lee-Sepsick Meets with Members of Congress to Raise Awareness of the Company and Discuss Women's Healthcare Initiatives	19.04.
Femasys CEO and Founder Kathy Lee-Sepsick Meets with Members of Congress to Raise Awareness of the Company and Discuss Women’s Healthcare Initiatives	18.04.
Femasys Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28.03.
Femasys Announces Financial Results for Year Ended December 31, 2023 and Provides Corporate Update	28.03.
Femasys Announces Financial Results for Year Ended December 31, 2023 and Provides Corporate Update	28.03.
Femasys Announces Positive Topline Data from Pivotal Trial for its FDA-Cleared FemaSeed for the Treatment of Infertility	21.03.
Femasys Invites Investors to View Fireside Chat Today, March 21, 2024, to Discuss the Infertility Treatment Landscape	21.03.
Femasys Announces Positive Topline Data from Pivotal Trial for its FDA-Cleared FemaSeed® for the Treatment of Infertility	20.03.
Femasys Announces Positive Topline Data from Pivotal Trial for its FDA-Cleared FemaSeed® for the Treatment of Infertility	20.03.
Femasys Inc. Announces Positive Topline Data from Pivotal Trial for Its Fda-Cleared Femaseed®? for the Treatment of Infertility	20.03.
Femasys to Participate in Fireside Chat to Discuss the Infertility Treatment Landscape on March 21, 2024	13.03.
Femasys Completes the First In-Office Commercial Procedure with the FDA-Cleared FemaSeed Infertility Solution	06.03.
Femasys Completes the First In-Office Commercial Procedure with the FDA-Cleared FemaSeed Infertility Solution	06.03.
Femasys FemaSeed FDA Clearance Brings Timely Access to a First-Line Infertility Treatment Option as an Alternative to IVF	29.02.
Femasys’ FemaSeed FDA Clearance Brings Timely Access to a First-Line Infertility Treatment Option as an Alternative to IVF	28.02.
Femasys’ FemaSeed FDA Clearance Brings Timely Access to a First-Line Infertility Treatment Option as an Alternative to IVF	28.02.
Femasys Inc. Advances Commercial Readiness with Appointment of Richard Spector to New Position of Chief Commercial Officer	06.02.
Femasys Inc. Appoints Richard Spector as Chief Commercial Officer	06.02.
Femasys Begins Patient Enrollment for Permanent Birth Control Candidate Trial	26.01.
Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at UC Davis Medical Center, a Hub for Innovation and Groundbreaking Research in Health Care for Women	26.01.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Femasys Inc.

Aktien

A3CYX9

US31447E1055

FEMY

Andere Sprachen

Filter